Dimensional Fund Advisors LP Surface Oncology, Inc. Transaction History

Dimensional Fund Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.61 - $1.03 $65,258 - $110,190	-106,981 Reduced 52.94%	95,083 $66,000
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.1 $449,834 - $899,669	-428,414 Reduced 67.95%	202,064 $210,000
Q2 2022 Aug 12, 2022	SELL	$1.42 - $3.15 $159,727 - $354,324	-112,484 Reduced 15.14%	630,478 $1.03 Million
Q1 2022 May 13, 2022	BUY	$2.65 - $5.08 $895,660 - $1.72 Million	337,985 Added 83.46%	742,962 $2.18 Million
Q4 2021 Feb 09, 2022	BUY	$4.73 - $7.9 $658,936 - $1.1 Million	139,310 Added 52.44%	404,977 $1.94 Million
Q3 2021 Nov 12, 2021	SELL	$5.16 - $7.98 $1.86 Million - $2.88 Million	-360,849 Reduced 57.6%	265,667 $2.01 Million
Q2 2021 Aug 12, 2021	BUY	$6.45 - $9.09 $806,262 - $1.14 Million	125,002 Added 24.92%	626,516 $4.67 Million
Q1 2021 May 14, 2021	BUY	$7.25 - $13.82 $2.41 Million - $4.59 Million	332,410 Added 196.57%	501,514 $3.91 Million
Q4 2020 Feb 25, 2021	BUY	$6.87 - $10.48 $1.16 Million - $1.77 Million	169,104 New	169,104 $1.56 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.